×

Bluebird Bio CEO on new study data: We're getting profound responses

6:38 AM ET Thu, 1 Dec 2016

CNBC's Meg Tirrell speaks with Bluebird Bio CEO Nick Leschly about his company's successful study of its multiple myeloma treatment as well as the election effect on the biotech sector.